Plastic surgeon Lisa Cassileth, MD, told Allure's Perspectives podcast in an interview with editor in chief Jessica Cruel that the rise in GLP-1 prescriptions is changing the surgeries she is asked to perform. Cassileth, the first female chief of plastic surgery at Cedars-Sinai Medical Center, says patients losing 20 to 30 pounds on the drugs are arriving with a problem that is less about size than about placement.

The drugs she names are Wegovy and Zepbound, the brand versions of semaglutide and tirzepatide, peptide-based medications prescribed for obesity and type 2 diabetes. They work on appetite and blood sugar regulation, and the cosmetic knock-on effects of the weight loss they produce are now a talking point in aesthetic medicine.

Fewer reductions, more lifts

Requests for breast reductions have gone down in her practice, Cassileth says, while lifts have gone up. After significant weight loss a patient's breasts may be the size they want, "but [the volume] is in the wrong place," with tissue concentrated in the lower half and little in the upper.

She attributes that to excess, lax skin, which has also changed her surgical approach. "The lifts used to rely on the skin being tightened," she says, and skin that has already stretched out is skin that has "already failed."

What the mesh does

Her workaround is absorbable mesh. It "holds the breast in position, but over time it dissolves and leaves scar tissue and collagen tissue where the body is replacing the mesh," she says, which she describes as giving her more control over the final shape.

Where the evidence stops

All of this is one surgeon's account of her own caseload, not published data. Cassileth offers no trial, no patient numbers and no denominator for the shift she describes, and Allure does not cite one. That is worth saying plainly, because "surgeons are seeing more of X" is exactly the kind of observation that hardens into a statistic once it has been repeated enough times.

Her implant figures come with a similar caveat. She says Motiva implants have been available in Europe for over a decade with less than 1% rupture at 10 years, against the older counseling line of roughly 10% at 10 years, but the source for those numbers is her.

The open question

Whether GLP-1 prescribing is genuinely reshaping aesthetic surgery nationally, or whether one Beverly Hills practice is a poor proxy for anywhere else, is not something a podcast episode can settle. Nobody has published the caseload data that would.